A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. Demand for the drugmaker’s Paxlovid treatment spurred by the latest COVID wave and a U.S. national stockpile delivery led to $2.7 billion in sales for the drug, Pfizer said Tuesday. The company also cited sales growth from several other drugs, as total revenue climbed 31% to $17.7 billion in the recently completed quarter. Adjusted earnings totaled $1.06 per share. Analysts expect earnings of 61 cents per share in the third quarter on $14.92 billion in revenue, according to FactSet. Pfizer shares climbed in early trading. The drugmaker said it made a one-time del
Hence then, the article about pfizer rides paxlovid sales growth to better than expected third quarter was published today ( ) and is available onNews10NBC ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Pfizer rides Paxlovid sales growth to better-than-expected third quarter )